Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide

被引:15
|
作者
Lou, Jie [1 ]
Smith, Robert J. [2 ,3 ]
机构
[1] Shanghai Univ, Dept Math, Shanghai 200444, Peoples R China
[2] Univ Ottawa, Dept Math, Ottawa, ON K1N 6N5, Canada
[3] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Enfuvirtide; Fusion inhibitors; Antiretroviral therapy; Mathematical model; Adherence; IMMUNOLOGICAL MODEL; DRUG-RESISTANCE; INFECTION; DYNAMICS; THERAPY; ENTRY;
D O I
10.1016/j.jtbi.2010.09.039
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recently, the first drug in a new class of antiretroviral HIV drugs was approved, the fusion inhibitor enfuvirtide. We develop a mathematical model that describes the binding of the virus to T cells. We model the effect of enfuvirtide upon this process using impulsive differential equations. We find equilibria and determine stability in the case of no therapy and then when therapy is taken with perfect adherence. We determine analytical thresholds for the dosage and dosing intervals to ensure the disease-free equilibrium remains stable. We also explore the effects of partial adherence. Our theoretical results suggest that partial adherence may, at times, be worse than no therapy at all, but at other times may in fact as good as perfect adherence. It follows that patients should be counselled on the importance of adherence to this new antiretroviral drug. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [21] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    Lalezari, JP
    Henry, K
    O'Hearn, M
    Montaner, JSG
    Piliero, PJ
    Trottier, B
    Walmsley, S
    Cohen, C
    Kuritzkes, DR
    Eron, JJ
    Chung, J
    DeMasi, R
    Donatacci, L
    Drobnes, C
    Delehanty, J
    Salgo, M
    Farthing, C
    Graham, E
    Packard, M
    Ngo, L
    Lederman, M
    Buam, J
    Pollard, R
    Rauf, S
    Silkowski, W
    Thompson, M
    Rucker, A
    Harris, M
    Larsen, G
    Preseon, S
    Cunningham, D
    Guimaraes, D
    Bertasso, A
    Kinchelow, T
    Myers, R
    Phoenix, BCBP
    Skolnik, PR
    Adams, B
    Leite, OHM
    Oliveira, M
    Lefebvre, E
    Gomez, B
    Foy, KB
    Lampiris, H
    Charles, S
    Dobkin, J
    Crawford, M
    Slom, T
    Murphy, R
    Mikaitis, T
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22): : 2175 - 2185
  • [22] A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
    Myers, Sarah A.
    Selim, Angelica A.
    McDaniel, Margaret A.
    Hall, Russell
    Zhang, Ying
    Bartlett, John A.
    True, Andrea L.
    ANTIVIRAL THERAPY, 2006, 11 (07) : 935 - 939
  • [23] Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study
    Ahmadi, Khadijeh
    Farasat, Alireza
    Rostamian, Mosayeb
    Johari, Behrooz
    Madanchi, Hamid
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (12): : 5566 - 5576
  • [24] Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART
    Moyle, G
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) : 213 - 217
  • [25] HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes
    Matos, Pedro M.
    Castanho, Miguel A. R. B.
    Santos, Nuno C.
    PLOS ONE, 2010, 5 (03):
  • [26] Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations
    Clotet, B
    Raffi, F
    Cooper, D
    Delfraissy, JF
    Lazzarin, A
    Moyle, G
    Rockstroh, J
    Soriano, V
    Schapiro, J
    AIDS, 2004, 18 (08) : 1137 - 1146
  • [27] Section: bioprocessing and biological engineering gene fragment polymerization for increased yield of recombinant HIV fusion inhibitor enfuvirtide
    Gudipudi, Anil
    Bajji, Chitra
    Kosana, Ravikanth Reddy
    Panati, Kalpana
    Lomada, Dakshayani
    Tatireddigari, Venkat R. R. Arva
    Narala, Venkata Ramireddy
    BIOTECHNOLOGY LETTERS, 2014, 36 (09) : 1761 - 1769
  • [28] Mathematical Modelling of Enfuvirtide and Protease Inhibitors as Combination Therapy for HIV
    Chowdhury, Sonia
    Roy, Priti Kumar
    Smith, Robert J.
    INTERNATIONAL JOURNAL OF NONLINEAR SCIENCES AND NUMERICAL SIMULATION, 2016, 17 (06) : 259 - 275
  • [29] Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection
    Hardy, N
    Skolnik, PR
    PHARMACOTHERAPY, 2004, 24 (02): : 198 - 211
  • [30] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America (vol 348, pg 2175, 2003)
    Lalezari, JP
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11): : 1100 - 1100